In the GlaxoSmithKline case, who was the whistleblower?
GETNICK: That case also came under investigation because of the case that George filed. George pointed out in his complaint, in his disclosure statement, and in his communications with the government that if you look at the modus operandi that existed in Bayer’s dealings with Kaiser, and then looked at the national drug code numbers on other prescription drugs for other companies, one could reasonably infer that this practice was not limited to Bayer on these two drugs. One of the companies that was brought to the attention of the government by George in his initial complaint was GlaxoSmithKline. That led the government to open an investigation into that matter. And that resulted in the settlement we saw yesterday. The GlaxoSmithKline settlement was $87 million. The Bayer settlement was $251 million for the settlement of the civil portion of the case, and then the additional $6 million criminal fine. The company pled guilty to failing to list private label Cipro with the Food and Drug
